{"id":"bacillus-calmette-guerin-bcg","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Dysuria"},{"rate":"40-60","effect":"Urinary frequency"},{"rate":"20-40","effect":"Hematuria"},{"rate":"10-20","effect":"Fever"},{"rate":"10-20","effect":"Malaise"},{"rate":"<1","effect":"BCG sepsis (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BCG works by activating innate and adaptive immune responses through pattern recognition receptors on immune cells. When instilled directly into the bladder, it triggers local inflammation and recruitment of immune cells that target bladder cancer cells. The exact mechanism involves activation of dendritic cells, T cells, and natural killer cells that recognize tumor-associated antigens.","oneSentence":"BCG is a live attenuated mycobacterial vaccine that stimulates the immune system to recognize and destroy cancer cells, particularly in the bladder.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:30:40.522Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-muscle invasive bladder cancer (NMIBC), including carcinoma in situ"},{"name":"Bladder cancer prophylaxis after transurethral resection"}]},"trialDetails":[{"nctId":"NCT04164082","phase":"PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-03-18","conditions":"Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8","enrollment":161},{"nctId":"NCT07222488","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-09","conditions":"Bladder Cancer, Urinary Bladder Neoplasms","enrollment":45},{"nctId":"NCT06800963","phase":"PHASE1, PHASE2","title":"ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-10-15","conditions":"NMIBC","enrollment":40},{"nctId":"NCT07495072","phase":"NA","title":"Early vs Delayed Intravesical Blad-Care During BCG Therapy","status":"RECRUITING","sponsor":"BLAD-HYA Group","startDate":"2025-11-03","conditions":"Urinary Bladder Neoplasms, BCG-Induced Cystitis","enrollment":56},{"nctId":"NCT06833073","phase":"PHASE2","title":"A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-11","conditions":"Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ","enrollment":308},{"nctId":"NCT03091660","phase":"PHASE3","title":"S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2017-02-24","conditions":"Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma","enrollment":1000},{"nctId":"NCT02138734","phase":"PHASE1, PHASE2","title":"A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2014-07-21","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":596},{"nctId":"NCT05037279","phase":"PHASE3","title":"Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)","status":"RECRUITING","sponsor":"Verity Pharmaceuticals Inc.","startDate":"2024-04-24","conditions":"Bladder Cancer, Bladder Cancer Recurrent, Neoplasm Recurrence","enrollment":540},{"nctId":"NCT06257212","phase":"PHASE4","title":"Live Vaccines and Innate Immune Training in COPD.","status":"COMPLETED","sponsor":"Josefin Eklöf","startDate":"2024-02-28","conditions":"Trained Innate Immunity, COPD","enrollment":60},{"nctId":"NCT05714202","phase":"PHASE3","title":"A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-03-23","conditions":"Bladder Cancer","enrollment":1135},{"nctId":"NCT07483970","phase":"PHASE1","title":"A Phase I/II Study of JL19001 Injection Alone or in Combination With BCG in Subjects With High Risk Non-Muscle Invasive Bladder Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Jecho Biopharmaceuticals Co., Ltd.","startDate":"2026-03-30","conditions":"High Risk Non-muscle Invasive Bladder Cancer","enrollment":18},{"nctId":"NCT07480356","phase":"PHASE3","title":"Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"Protara Therapeutics","startDate":"2026-05","conditions":"Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ","enrollment":284},{"nctId":"NCT05547464","phase":"PHASE1, PHASE2","title":"Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2023-07-31","conditions":"Tuberculosis","enrollment":497},{"nctId":"NCT07322263","phase":"PHASE2","title":"Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC","status":"NOT_YET_RECRUITING","sponsor":"Michael A. O'Donnell","startDate":"2026-04-01","conditions":"Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Urothelial Carcinoma","enrollment":174},{"nctId":"NCT06211764","phase":"PHASE3","title":"A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-04-09","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":272},{"nctId":"NCT03258593","phase":"PHASE1","title":"Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-07","conditions":"Urinary Bladder Neoplasms","enrollment":15},{"nctId":"NCT07342517","phase":"PHASE3","title":"A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy","status":"WITHDRAWN","sponsor":"Relmada Therapeutics, Inc.","startDate":"2026-06-30","conditions":"Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder","enrollment":""},{"nctId":"NCT04452591","phase":"PHASE3","title":"Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin","status":"ACTIVE_NOT_RECRUITING","sponsor":"CG Oncology, Inc.","startDate":"2020-10-27","conditions":"Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer","enrollment":190},{"nctId":"NCT07474519","phase":"PHASE4","title":"Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2026-02-26","conditions":"Non-Muscle Invasive Bladder Carcinoma","enrollment":40},{"nctId":"NCT05316155","phase":"PHASE1, PHASE2","title":"Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-04-11","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":235},{"nctId":"NCT04640623","phase":"PHASE2","title":"A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-12-18","conditions":"Urinary Bladder Neoplasms","enrollment":220},{"nctId":"NCT07468851","phase":"PHASE1, PHASE2","title":"A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2026-06-10","conditions":"High-risk Non-muscle-invasive Bladder Cancer","enrollment":180},{"nctId":"NCT05843448","phase":"PHASE1","title":"IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2023-04-19","conditions":"High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8","enrollment":30},{"nctId":"NCT06919965","phase":"PHASE3","title":"A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-09-10","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":220},{"nctId":"NCT05947890","phase":"PHASE2","title":"Evaluating the Safety and Immunogenicity of MTBVAC","status":"RECRUITING","sponsor":"HIV Vaccine Trials Network","startDate":"2024-01-30","conditions":"HIV I Infection, Tuberculosis","enrollment":276},{"nctId":"NCT07206225","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-11-06","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":294},{"nctId":"NCT07464145","phase":"PHASE3","title":"A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"Relmada Therapeutics, Inc.","startDate":"2026-06","conditions":"Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder","enrollment":393},{"nctId":"NCT05943106","phase":"PHASE3","title":"BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-08-11","conditions":"Non-Muscle- Invasive Bladder Cancer","enrollment":100},{"nctId":"NCT06050356","phase":"PHASE1","title":"First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b","status":"ACTIVE_NOT_RECRUITING","sponsor":"Statens Serum Institut","startDate":"2024-03-14","conditions":"Healthy","enrollment":140},{"nctId":"NCT06443944","phase":"","title":"An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG","status":"AVAILABLE","sponsor":"CG Oncology, Inc.","startDate":"","conditions":"Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma, Urologic Cancer","enrollment":""},{"nctId":"NCT07447999","phase":"","title":"Multimodal Deep Learning Model for Predicting the Apnea-Hypopnea Index in Obstructive Sleep","status":"RECRUITING","sponsor":"Fu Jen Catholic University","startDate":"2025-09-05","conditions":"Obstructive Sleep Apnea (OSA), Polysomnography","enrollment":150},{"nctId":"NCT07000084","phase":"PHASE3","title":"Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2025-07-17","conditions":"Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8","enrollment":330},{"nctId":"NCT06545955","phase":"PHASE3","title":"A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Ferring Pharmaceuticals","startDate":"2024-10-01","conditions":"Non-muscle Invasive Bladder Cancer With Carcinoma in Situ","enrollment":250},{"nctId":"NCT01778569","phase":"","title":"The Psoriasis, Atherosclerosis, and Cardiometabolic Disease Initiative (PACI)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2013-01-22","conditions":"Metabolic Disease, Cardiovascular Disease, Inflammation","enrollment":386},{"nctId":"NCT07445308","phase":"PHASE1, PHASE2","title":"The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.","status":"NOT_YET_RECRUITING","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2026-03-12","conditions":"NMIBC","enrollment":120},{"nctId":"NCT04701151","phase":"PHASE4","title":"NORTH-REG Dwell-Time Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jørgen Bjerggaard Jensen","startDate":"2021-02-03","conditions":"Side Effect of Drug","enrollment":314},{"nctId":"NCT05538663","phase":"PHASE3","title":"Intravesical BCG vs GEMDOCE in NMIBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-02-07","conditions":"Non-muscle-invasive Bladder Cancer","enrollment":870},{"nctId":"NCT05644041","phase":"PHASE2","title":"Intravesical Gem/Doce in Patients With NMIBC","status":"RECRUITING","sponsor":"University of Arizona","startDate":"2023-03-01","conditions":"Urinary Bladder Cancer","enrollment":25},{"nctId":"NCT06579157","phase":"","title":"Pressure-Sensing Mattresses and Mechanical Ventilation Weaning in Neonatal","status":"RECRUITING","sponsor":"Fu Jen Catholic University","startDate":"2024-11-10","conditions":"Bronchopulmonary Dysplasia","enrollment":60},{"nctId":"NCT04172675","phase":"PHASE2","title":"A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-02-28","conditions":"Urinary Bladder Neoplasms","enrollment":107},{"nctId":"NCT07424287","phase":"PHASE3","title":"A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-03","conditions":"NMIBC","enrollment":236},{"nctId":"NCT05710848","phase":"PHASE1, PHASE2","title":"A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer","status":"RECRUITING","sponsor":"SURGE Therapeutics","startDate":"2023-07-11","conditions":"Non-muscle-invasive Bladder Cancer","enrollment":75},{"nctId":"NCT06972615","phase":"PHASE2","title":"Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy","status":"NOT_YET_RECRUITING","sponsor":"BLATAM","startDate":"2026-04-01","conditions":"Non Muscle Invasive Bladder Cancer","enrollment":37},{"nctId":"NCT05591339","phase":"PHASE4","title":"Diabetes Diagnosis, Management, Prevention and Education in Guinea-Bissau","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bandim Health Project","startDate":"2023-12-01","conditions":"Diabetes Mellitus, BCG Vaccination Reaction","enrollment":200},{"nctId":"NCT06026332","phase":"","title":"ADSTILADRIN Early Utilization and Outcomes in the Real World Setting","status":"TERMINATED","sponsor":"Ferring Pharmaceuticals","startDate":"2023-09-15","conditions":"Bladder Cancer","enrollment":202},{"nctId":"NCT04658680","phase":"PHASE4","title":"Can BCG Vaccination at First Health-facility Contact Reduce Early Infant Mortality?","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bandim Health Project","startDate":"2021-02-25","conditions":"Infant Mortality, BCG","enrollment":22800},{"nctId":"NCT06245603","phase":"NA","title":"A Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Istituto Oncologico Veneto IRCCS","startDate":"2024-12-20","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":200},{"nctId":"NCT04564781","phase":"","title":"Predicting BCG Response","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2020-09-18","conditions":"Bladder Cancer","enrollment":400},{"nctId":"NCT04752722","phase":"PHASE1, PHASE2","title":"LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve","status":"RECRUITING","sponsor":"enGene, Inc.","startDate":"2021-04-22","conditions":"Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ","enrollment":350},{"nctId":"NCT04453293","phase":"PHASE3","title":"Immunization With BCG Vaccine to Prevent Tuberculosis Infection","status":"TERMINATED","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2021-12-01","conditions":"Tuberculosis Infection","enrollment":16},{"nctId":"NCT04165317","phase":"PHASE3","title":"A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2019-12-30","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":1068},{"nctId":"NCT07283835","phase":"PHASE2","title":"Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin","status":"RECRUITING","sponsor":"Lepu Biopharma Co., Ltd.","startDate":"2025-12-04","conditions":"Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer","enrollment":16},{"nctId":"NCT04630730","phase":"PHASE2","title":"Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2022-06-24","conditions":"Bladder Cancer","enrollment":46},{"nctId":"NCT07307456","phase":"PHASE2","title":"Tremelimumab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration","status":"RECRUITING","sponsor":"Changhai Hospital","startDate":"2025-12-08","conditions":"Bladder Cancer","enrollment":31},{"nctId":"NCT06747455","phase":"PHASE3","title":"BCG for Therapeutic Use Phase Ⅲ Clinical Trial","status":"RECRUITING","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2025-04-08","conditions":"BCG","enrollment":438},{"nctId":"NCT05537038","phase":"PHASE1","title":"Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2023-04-18","conditions":"Tuberculosis","enrollment":120},{"nctId":"NCT03711032","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-24","conditions":"High-risk Non-muscle Invasive Bladder Cancer","enrollment":1397},{"nctId":"NCT05327647","phase":"PHASE2","title":"A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"CHU de Quebec-Universite Laval","startDate":"2022-06-23","conditions":"Non-Muscle Invasive Bladder Cancer","enrollment":160},{"nctId":"NCT06845358","phase":"PHASE1","title":"Safety and Challenge Study of BCG TICE(R) Vaccination to Test Tuberculosis Immunity in Heathy Humans","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-11-26","conditions":"Tuberculosis","enrollment":""},{"nctId":"NCT05024773","phase":"PHASE3","title":"Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)","status":"RECRUITING","sponsor":"Fidia Farmaceutici s.p.a.","startDate":"2022-12-29","conditions":"Bladder Carcinoma in Situ (CIS)","enrollment":112},{"nctId":"NCT05592223","phase":"PHASE1","title":"Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-12-06","conditions":"Tuberculosis","enrollment":20},{"nctId":"NCT04507126","phase":"PHASE2","title":"A Pilot Study of the Effects of BCG Immunization on CSF and Blood-based Biomarkers in Older Adults.","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2021-03-01","conditions":"Healthy","enrollment":20},{"nctId":"NCT06670755","phase":"NA","title":"ID93/GLA-SE Vaccination + BCG Challenge","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2024-12-18","conditions":"Tuberculosis","enrollment":48},{"nctId":"NCT02081326","phase":"PHASE2","title":"Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2015-06","conditions":"Diabetes Mellitus, Type One, Diabetes Mellitus, Type I, Autoimmune Diabetes","enrollment":150},{"nctId":"NCT05180591","phase":"PHASE2","title":"Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-03-22","conditions":"Diabetes Mellitus, Type 1, Diabetes type1, Autoimmune Diabetes","enrollment":150},{"nctId":"NCT05866536","phase":"PHASE2","title":"Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-05-04","conditions":"Diabetes Mellitus, Type 1 Diabetes, Diabetes type1","enrollment":100},{"nctId":"NCT06148025","phase":"PHASE4","title":"Antibiotics and Vaccine Immune Responses Study","status":"RECRUITING","sponsor":"South Australian Health and Medical Research Institute","startDate":"2023-11-23","conditions":"Vaccine Response Impaired","enrollment":348},{"nctId":"NCT07268339","phase":"PHASE3","title":"A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer.","status":"NOT_YET_RECRUITING","sponsor":"The Christie NHS Foundation Trust","startDate":"2025-12-01","conditions":"High-Risk Non-Muscle Invasive Bladder Cancer","enrollment":328},{"nctId":"NCT05768347","phase":"PHASE1","title":"Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-08-10","conditions":"Urothelial Carcinoma, Non-Invasive Bladder Urothelial Carcinoma","enrollment":9},{"nctId":"NCT03528694","phase":"PHASE3","title":"Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-05-14","conditions":"Non-muscle-invasive Bladder Cancer","enrollment":1018},{"nctId":"NCT03945162","phase":"PHASE2","title":"Intravesical Photodynamic Therapy (\"PDT\") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Patients","status":"RECRUITING","sponsor":"Theralase® Technologies Inc.","startDate":"2019-08-30","conditions":"Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Unresponsive/Intolerant to BCG","enrollment":90},{"nctId":"NCT04412070","phase":"","title":"Assessement of the Concordance of Genomic Alterations Between Urine and Tissue in High-Risk NMIBC Patients","status":"TERMINATED","sponsor":"Hopital Foch","startDate":"2021-07-30","conditions":"Bladder Cancer","enrollment":20},{"nctId":"NCT02625961","phase":"PHASE2","title":"Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-02-10","conditions":"Bladder Cancer","enrollment":296},{"nctId":"NCT07231809","phase":"NA","title":"Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients","status":"NOT_YET_RECRUITING","sponsor":"AC.TA. S.r.l.","startDate":"2026-01-15","conditions":"Non Muscle Invasive Bladder Cancer, Bladder Cancer, Carcinoma in Situ of Bladder","enrollment":50},{"nctId":"NCT06246851","phase":"NA","title":"BCG Revaccination Study in Diabetic and Non-Diabetic Adults","status":"ENROLLING_BY_INVITATION","sponsor":"University of Oxford","startDate":"2024-04-03","conditions":"Tuberculosis","enrollment":36},{"nctId":"NCT05672615","phase":"","title":"Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-03-21","conditions":"Non-Muscle Invasive Bladder Cancer","enrollment":42},{"nctId":"NCT04386746","phase":"PHASE2","title":"Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2020-07-29","conditions":"Urothelial Carcinoma Bladder, Bladder Cancer","enrollment":27},{"nctId":"NCT03504163","phase":"PHASE2","title":"Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-06-27","conditions":"Bladder Cancer","enrollment":45},{"nctId":"NCT03933826","phase":"","title":"CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2019-07-09","conditions":"Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer","enrollment":570},{"nctId":"NCT06929286","phase":"PHASE3","title":"A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-04-11","conditions":"Non-Muscle Invasive Bladder Cancer","enrollment":125},{"nctId":"NCT06829823","phase":"PHASE2","title":"Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-11","conditions":"Non-muscle Invasive Bladder Cancer (NMIBC)","enrollment":20},{"nctId":"NCT03022825","phase":"PHASE2, PHASE3","title":"QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2017-06-02","conditions":"Bladder Cancer","enrollment":190},{"nctId":"NCT07182838","phase":"EARLY_PHASE1","title":"Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic Mix","status":"ACTIVE_NOT_RECRUITING","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","startDate":"2025-09-12","conditions":"HIV Infections","enrollment":20},{"nctId":"NCT07207824","phase":"PHASE3","title":"DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-12-01","conditions":"Bladder (Urothelial, Transitional Cell) Cancer, NMIBC","enrollment":182},{"nctId":"NCT06781879","phase":"PHASE4","title":"Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Jakob Kristian Jakobsen","startDate":"2025-06-01","conditions":"Non-Muscle Invasive Bladder Cancer","enrollment":272},{"nctId":"NCT07189793","phase":"PHASE2","title":"Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10","conditions":"Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Carcinoma in Situ of Bladder","enrollment":106},{"nctId":"NCT06704191","phase":"PHASE1, PHASE2","title":"In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-04-21","conditions":"Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8","enrollment":40},{"nctId":"NCT04149574","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2020-01-15","conditions":"Urinary Bladder Neoplasms","enrollment":13},{"nctId":"NCT06388720","phase":"PHASE2","title":"The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy","status":"RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2024-11-19","conditions":"Bladder Cancer","enrollment":82},{"nctId":"NCT06351904","phase":"PHASE1","title":"A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy","status":"RECRUITING","sponsor":"Ractigen Therapeutics.","startDate":"2024-04-03","conditions":"Non-Muscle-Invasive Bladder Cancer (NMIBC)","enrollment":72},{"nctId":"NCT05126472","phase":"PHASE1","title":"Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-11-08","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":55},{"nctId":"NCT07152639","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of EEC for the Diagnosis of Mycobacterium Tuberculosis Infection in People Aged 3 Years and Above","status":"RECRUITING","sponsor":"Chengdu CoenBiotech Co., Ltd","startDate":"2025-08-09","conditions":"Tuberculosis","enrollment":1784},{"nctId":"NCT05519241","phase":"PHASE1","title":"A Phase I Intravesical PPM Therapy for NMIBC","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2022-10-10","conditions":"Non-muscle-invasive Bladder Cancer","enrollment":29},{"nctId":"NCT05704244","phase":"PHASE3","title":"Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ferring Pharmaceuticals","startDate":"2022-12-21","conditions":"Bladder Cancer","enrollment":25},{"nctId":"NCT05825950","phase":"","title":"Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2024-01-25","conditions":"Non-muscle-invasive Bladder Cancer","enrollment":600},{"nctId":"NCT05539989","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa","status":"WITHDRAWN","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2025-12-31","conditions":"Tuberculosis, HIV Infections","enrollment":""},{"nctId":"NCT07048496","phase":"NA","title":"Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-07-05","conditions":"Bladder Cancer","enrollment":50},{"nctId":"NCT07122414","phase":"PHASE1, PHASE2","title":"A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Suzhou Forlong Biotechnology Co., Ltd","startDate":"2024-08-16","conditions":"Non-muscle Invasive Bladder Cancer (NMIBC)","enrollment":80},{"nctId":"NCT05507671","phase":"PHASE3","title":"The Role of BCG Vaccine in the Clinical Evolution of COVID-19 and in the Efficacy of Anti-SARS-CoV-2 Vaccines","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oswaldo Cruz Foundation","startDate":"2021-05-27","conditions":"COVID-19","enrollment":556},{"nctId":"NCT07094711","phase":"PHASE2","title":"Safety, Immunogenicity, and Efficacy of Therapeutic Mycobacterium Bovis BCG (BOOST)","status":"NOT_YET_RECRUITING","sponsor":"University of Virginia","startDate":"2025-09-30","conditions":"Mycobacterium Avium-intracellulare Infection, Mycobacterium Infections, Nontuberculous","enrollment":48}],"_emaApprovals":[],"_faersSignals":[{"count":12,"reaction":"DRUG INEFFECTIVE"},{"count":12,"reaction":"DRUG INTOLERANCE"},{"count":12,"reaction":"NON-HODGKIN^S LYMPHOMA"},{"count":5,"reaction":"ARTHRALGIA"},{"count":5,"reaction":"RHEUMATOID ARTHRITIS"},{"count":4,"reaction":"JOINT SWELLING"},{"count":3,"reaction":"DRUG HYPERSENSITIVITY"},{"count":2,"reaction":"OFF LABEL USE"},{"count":2,"reaction":"PRODUCT USE ISSUE"},{"count":2,"reaction":"TUBERCULIN TEST POSITIVE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tice BCG"],"phase":"marketed","status":"active","brandName":"Bacillus Calmette-Guerin (BCG)","genericName":"Bacillus Calmette-Guerin (BCG)","companyName":"Massachusetts General Hospital","companyId":"massachusetts-general-hospital","modality":"Biologic","firstApprovalDate":"","aiSummary":"BCG is a live attenuated mycobacterial vaccine that stimulates the immune system to recognize and destroy cancer cells, particularly in the bladder. Used for Non-muscle invasive bladder cancer (NMIBC), including carcinoma in situ, Bladder cancer prophylaxis after transurethral resection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}